Abbvie to record $4 billion impairment charges on Stemcentrx assets

Abbvie Inc on Friday said https://bit.ly/2F9iUlb it will record an estimated $4 billion in impairment charges related to the scrapping of its development program of Rova-T, an investigational cancer therapy.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Publication date: Available online 19 March 2019Source: Carbohydrate PolymersAuthor(s): Tingting Luo, Jingtian Han, Feng Zhao, Xiaohong Pan, Baocheng Tian, Xiujuan Ding, Jing ZhangAbstractNovel chitosan-cystamine-retinoic acid conjugate (CS-SS-RA) was synthesized and could self-assemble into redox-sensitive micelles in aqueous environment with low critical micelle concentration value. CS-SS-RA micelles were characterized with spherical shape, desirable particle size, negative zeta potential, high paclitaxel (PTX) loading and encapsulation efficiency and redox-sensitivity. Hemolysis and cytotoxicity studies proved the safet...
Source: Carbohydrate Polymers - Category: Biomedical Science Source Type: research
William Oh, MD, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, Discusses Data On Racial Differences In Response To Novel Prostate Cancer Therapies. At The 2019 Genitourinary Can... Author: obr Added: 03/20/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Publication date: Available online 19 March 2019Source: European Journal of Integrative MedicineAuthor(s): Shiao Li Oei, Anja Thronicke, Matthias Kröz, Cornelia Herbstreit, Friedemann SchadAbstractIntroductionViscum album L. extracts (VA) are frequently used in integrative oncology to enhance health-related quality of life. As a central aspect of well-being is associated with feeling warm or cold the internal coherence scale (ICS) questionnaire including the thermo coherence measurement was utilized.MethodsA prospective observational longitudinal cohort study was conducted, using data from the Network Oncology clinica...
Source: European Journal of Integrative Medicine - Category: Complementary Medicine Source Type: research
Far too often, cancer patients and their doctors aren ’t aware of all the side effects that accompany new cancer therapies. Some of these new medications might cause fatigue, muscle aches, general pain and discomfort. A lack of information can lead to patients being unprepared to manage their symptoms or even cause some to delay or stop treatment all together. Historically, many clinical trials did not have a method to analyze or widely report the patient’s experience while undergoing a therapy.  Researchers at UCLA and across the country are trying to change that. To help people in making better-informed ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Publication date: 18 March 2019Source: Cancer Cell, Volume 35, Issue 3Author(s): Niamh McDermott, Erika S. Buechelmaier, Simon N. PowellTumors resistant to PARP inhibitors frequently show signs of replication stress, with hyper-activated PARP. In this issue of Cancer Cell, Pillay et al. demonstrate that inhibiting PAR-chain turnover results in cell-cycle arrest, which is cytotoxic when combined with cell-cycle checkpoint inhibition and constitutes a novel cancer therapy.
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
Authors: Wu H, Jiang W, Li B, Yang H, Zhao X, Zhang H, Wang S, Peng L, Wang L, Wang X, Dai G, Fang C Abstract The expression of leucine aminopeptidase 3 (LAP3) is associated with the prognosis for and malignant transformation of many types of tumors. Therefore, a LAP3 inhibitor may represent a new strategy for cancer therapy. Evaluating the suppression of enzyme activity by an LAP3 inhibitor is essential. Right now, leucine aminopeptidases (LAPs) purified from the porcine kidneys are the only enzymes that can be used to evaluate the suppression of enzyme activity by an LAP3 inhibitor. This approach cannot accuratel...
Source: Drug Discoveries and Therapeutics - Category: Drugs & Pharmacology Tags: Drug Discov Ther Source Type: research
fellner Antibody-drug conjugates (ADCs) combine the tumor selectivity of antibodies with the potency of cytotoxic small molecules thereby constituting antibody-mediated chemotherapy. As this inherently limits the adverse effects of the chemotherapeutic, such approaches are heavily pursued by pharma and biotech companies and have resulted in four FDA (Food and Drug Administration)-approved ADCs. However, as with other cancer therapies, durable responses are limited by the fact that under cell stress exerted by these drugs, tumors can acquire mechanisms of escape. Resistance can develop against the antibody component of ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
In this study, a series of chalcone derivatives was screened by in vitro cytotoxicity against the wild type (A431 and A549) and mutant EGFR (H1975 and H1650) cancer cell lines, and, subsequently, tested for EGFR-tyrosine kinase (TK) inhibition. From the experimental screening, all chalcones seemed to be more active against the A431 than the A549 cell line, with chalcones 1c, 2a, 3e, 4e, and 4t showing a more than 50% inhibitory activity against the EGFR-TK activity and a high cytotoxicity with IC50 values of < 10 µM against A431 cells. Moreover, these five chalcones showed more potent on H1975 (T790M/L858R...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
New J. Chem., 2019, Accepted Manuscript DOI: 10.1039/C9NJ00263D, PaperDong Xu, Muhammad A Tahir, Liwu Zhang, Christian G. Sch äfer Here we report a straight forward synthetic procedure for the preparation of metal-containing polymer microspheres with combined magnetic resonance imaging (MRI) as well as controlled anti-cancer drug release functionality confined... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - New J. Chem. latest articles - Category: Chemistry Authors: Source Type: research
acute;gyi T Abstract Tyrosine kinases play crucial roles in cellular development and tumorigenesis. Tyrosine kinase inhibitors (TKIs) are effective and widely used drug molecules in targeted cancer therapies. Altered expressions of protooncogenes and tumor suppressor genes after DMBA (7,12-dimethylbenz[a]anthracene) treatment have been described as early markers of tumor induction; however their tissue-specific effects remain still unclear. Our study was aimed at examining the short-term possible antineoplastic and chemopreventive effects of a TKI compound (imatinib mesylate) on a DMBA-induced mouse tumor model. I...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health